Hubei Biocause Pharmaceutical Co., Ltd. Stock

Equities

000627

CNE000000F48

Life & Health Insurance

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
2.29 CNY -3.78% Intraday chart for Hubei Biocause Pharmaceutical Co., Ltd. -3.78% -19.37%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 49.31B 6.82B Sales 2023 49.66B 6.87B Capitalization 14.03B 1.94B
Net income 2022 274M 37.91M Net income 2023 -652M -90.22M EV / Sales 2022 0.35 x
Net Debt 2022 1.76B 244M Net cash position 2023 2.73B 378M EV / Sales 2023 0.23 x
P/E ratio 2022
52.7 x
P/E ratio 2023
-21.8 x
Employees 1,765
Yield 2022
3.48%
Yield 2023
-
Free-Float 31.71%
More Fundamentals * Assessed data
Dynamic Chart
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023 MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million. CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period MT
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period MT
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023 CI
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022 CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5% MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
More news
1 day-0.83%
1 month-5.18%
3 months-5.56%
6 months-24.44%
Current year-16.20%
More quotes
1 week
2.34
Extreme 2.34
2.48
1 month
2.19
Extreme 2.19
2.52
Current year
2.11
Extreme 2.11
3.08
1 year
2.11
Extreme 2.11
3.91
3 years
2.11
Extreme 2.11
4.08
5 years
2.11
Extreme 2.11
7.95
10 years
2.11
Extreme 2.11
17.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 20-05-25
Chairman 52 96-05-31
Director of Finance/CFO 57 20-05-25
Members of the board TitleAgeSince
Chairman 61 15-03-10
Director/Board Member 62 03-03-31
Director of Finance/CFO 57 20-05-25
More insiders
Date Price Change Volume
24-05-07 2.29 -3.78% 35 042 100
24-05-07 2.38 -0.83% 31,546,710
24-05-06 2.4 +0.84% 39,576,000
24-04-30 2.38 -4.03% 36,809,700

End-of-day quote Shenzhen S.E., May 06, 2024

More quotes
Hubei Biocause Pharmaceutical Co.,Ltd. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The Company is also involved in pharmaceutical business and chemical business. The Company’s products include polypropylene and Ibuprofen. The Company distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 000627 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW